No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Specialties
Based in South Korea, i-SENS, Inc. specializes in the provision of diagnostic biosensor technology. Its product portfolio encompasses a range of point-of-care (POC) testing equipment, including analyzers for HbA1c, blood gas, electrolytes, and PT/INR. Additionally, the company supplies the CareSens line of blood glucose monitors, along with lancing and various complementary medical devices, and offers diabetes management services. The firm's solutions are distributed internationally, reaching approximately 110 nations, notably across the United States, Japan, and European markets. Established in 2000, i-SENS, Inc. maintains its corporate headquarters in Seoul, South Korea.
www.i-sens.comNo one on the platform currently holds 099190.KQ.
No tracked institution reports a position in 099190.KQ as of their last filing.
No one on the platform has traded 099190.KQ yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | — | — | — | |||
| Rev. Growth % | 8.4% | 9.2% | ||||
| Profit Margin % | -1.6% | 3.2% | 7.8% | |||
| Free Cash Flow Margin % | -2.4% | -6.3% | 0.4% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $342.5B | +8.5% | $389.00 | $299.14–$478.86 | — | 2 |
| 2027 | $379.8B | +10.9% | $611.00 | $389.62–$832.38 | — | 2 |
| 2028 | $419.0B | +10.3% | $790.00 | $779.47–$800.53 | — | 1 |
| 2029 | $616.0B | +47.0% | $0.00 | $0.00–$0.00 | — | 0 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 099190.KQi-SENS, Inc. | $16260.00 | +0.00% | $465.8B | — |
| 001060.KSJW Pharmaceutical Corporation | $27100.00 | +0.00% | $625.8B | — |
| 001065.KSJW Pharmaceutical Corporation | $22350.00 | -0.22% | $394.3B | — |
| 041830.KQInBody Co.,Ltd | $58300.00 | +2.82% | $777.8B | — |
| 048410.KQHyundai Bioscience Co., Ltd. | $6420.00 | -2.87% | $619.6B | — |
| 053030.KQBINEX Co., Ltd. | $6380.00 | -1.09% |
Source: Financial Modeling Prep · peers by sector/industry
| $203.2B |
| — |
| 060280.KQCurexo Inc. | $7970.00 | +0.63% | $328.8B | — |